First human test of new Heart-Kidney drug completed

NCT ID NCT06675175

Summary

This early-stage study tested the safety of an experimental oral drug called AZD4144 in people with both heart and kidney disease. Twenty-nine participants took either the drug or a placebo pill daily for 28 days. The main goal was to see if the drug was safe and to measure its effects on inflammation in the body.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Research Site

    Glendale, California, 91203, United States

  • Research Site

    Daytona Beach, Florida, 32117, United States

  • Research Site

    Jacksonville, Florida, 32216, United States

  • Research Site

    Miami, Florida, 33125, United States

  • Research Site

    Port Orange, Florida, 32127, United States

  • Research Site

    Tampa, Florida, 33603, United States

  • Research Site

    Farmington Hills, Michigan, 48334, United States

  • Research Site

    The Bronx, New York, 10455, United States

  • Research Site

    Sherman, Texas, 75092, United States

  • Research Site

    Pleven, 5800, Bulgaria

  • Research Site

    Sofia, 1527, Bulgaria

  • Research Site

    Gyöngyös, 3200, Hungary

  • Research Site

    Kistarcsa, 2143, Hungary

  • Research Site

    Bucharest, 11658, Romania

  • Research Site

    Cluj-Napoca, 400006, Romania

Conditions

Explore the condition pages connected to this study.